Lyell Immunopharma, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 0.66M7.76M10.65M84.68M0.13M0.06M
Operating items
Research & Development 63.59M182.24M138.69M159.19M182.94M171.60M
Selling, General & Administrative 39.15M46.88M89.06M117.31M66.98M52.04M
Other Operating Expenses 9.43M2.32M4.75M2.79M3.31M
Operating Expenses 102.75M219.69M225.43M271.74M247.14M358.82M
Operating Income -102.09M-211.94M-214.78M-187.06M-247.01M-358.75M
EBIT -102.09M-211.94M-214.78M-187.06M-247.01M-358.75M
Non-operating items
Interest & Investment Income 8.12M5.94M1.17M7.05M23.45M24.07M
Other Non Operating Income -35.41M1.53M-0.16M1.89M1.85M4.69M
Non Operating Income -35.41M7.46M-35.44M3.94M12.38M15.76M
Net income details
EBT -93.97M-206.00M-213.61M-180.00M-223.56M-334.69M
Profit After Tax -129.38M-204.47M-250.22M-183.12M-234.63M-342.99M
Income from Continuing Operations -93.97M-206.00M-213.61M-180.00M-223.56M-334.69M
Consolidated Net Income -93.97M-206.00M-213.61M-180.00M-223.56M-334.69M
Income towards Parent Company -93.97M-206.00M-213.61M-180.00M-223.56M-334.69M
Preferred Dividend Payments 1.14M3.58M
Net Income towards Common Stockholders -130.52M-208.05M-250.22M-183.12M-223.56M-334.69M
Additional items
EPS (Basic) -24.04-15.69-1.84-0.74-0.93-1.31
EPS (Weighted Average and Diluted) -24.04-15.69-1.84-0.74-0.93-1.31
Shares Outstanding (Weighted Average) 12.14M12.02M12.47M12.70M13.96M
Shares Outstanding (Diluted Average) 0.01M13.26M135.92M247.08M250.98M261.48M
EBITDA -128.92M-204.67M-252.10M-189.09M-227.13M-342.61M
Shares Outstanding 11.18M15.57M242.74M